Oral Squamous Cell Carcinoma Clinical Trial
— OSCCOfficial title:
Association of Salivary Amino Acid With Oral Squamous Cell Carcinoma Identified by Liquid Chromatography Mass Spectroscopy
Oral Squamous Cell Carcinoma (OSCC) is the most common oral malignancy worldwide. The prognosis of the OSCC patient is not significant despite the modern treatment facilities. Late presentation is one of the most crucial cause of this and for that reason, the importance of early diagnosis of OSCC should be the main concern. Till now, incisional biopsy followed by histopathological examination is the gold standard for diagnosis of oral cancer. The aim of the present study is to find out the association of salivary amino acid levels with oral squamous cell carcinoma, whether the levels are increased or decreased in the patient suffering from OSCC. This might be helpful for early diagnosis of oral cancer and better prognosis.
Status | Recruiting |
Enrollment | 110 |
Est. completion date | March 30, 2022 |
Est. primary completion date | March 20, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion criteria for case - Age: 18-70 years. - Both genders. - Patient with histo-pathologically diagnosedoral squamous carcinoma - Willing to participate in the study. Inclusion criteria for controls - Healthy patients without any malignancy - Patients relatively almost the same age group of cases Exclusion criteria for cases - Patients with severe periodontitis and multiple carious teeth. - Patients having other systemic diseases and cancer. - Patients who cannot fulfill the inclusion criteria. Exclusion criteria for controls - Having severe periodontal problemsor dental caries - Suffering from any cancer |
Country | Name | City | State |
---|---|---|---|
Bangladesh | Bangabandhu Sheikh Mujib Medical University (BSMMU) | Dhaka | |
Bangladesh | Bangladesh Reference Institute for Chemical Measurements | Dhaka | Dhanmondi |
Lead Sponsor | Collaborator |
---|---|
DR. MALA KHAN | Bangladesh Reference Institute of Chemical Measurements (BRICM) |
Bangladesh,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome of the study to establish a diagnostic test in the early detection of OSCC. | 1. Total 110 samples, 55 in each group (case and control) will be included in the study and a questionnaire will be filled up by each participant based on their sociodemographic characteristics, personal habit and also the tumor staging of confirmed cancer cases.
Saliva metabolite profiling of six amino acids (Alanine, Valine, Glycine, Phenylalanine, Isoleucine, Lysine) will be performed using LCMS/MS system. During metabolite profiling experiments, centroid data will be acquired for each sample from 50 to 1000 Da with a 0.10-sec scan time and a 0.01-sec interscan delay over an 18-min analysis time. 3. The LCMS/MS data of OSCC and control saliva samples will be analyzed to identify potential discriminant variables. Selecting the method, investigator will create dataset, Researcher would like to (i) detect Peaks and (ii) collect markers. The investigators can create dataset display, and at this point, it is also possible to automatically print data into a text file. |
From December,2020 to February, 2022 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04543266 -
Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
|
||
Not yet recruiting |
NCT06438939 -
NBI for Early Diagnosis of OPMD/OSCC
|
N/A | |
Recruiting |
NCT05024383 -
Dissecting the Heterogeneity of Oral Cancer Pain
|
N/A | |
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Not yet recruiting |
NCT06174428 -
Validity of Viome's Oral/Throat Cancer Test
|
||
Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
Recruiting |
NCT05069857 -
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
|
Phase 2 | |
Not yet recruiting |
NCT03619304 -
Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line
|
N/A | |
Active, not recruiting |
NCT01772706 -
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05893888 -
Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06055868 -
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
|
||
Not yet recruiting |
NCT06130007 -
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
|
Phase 2 | |
Recruiting |
NCT05798793 -
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT02739204 -
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05708209 -
The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
|
||
Recruiting |
NCT05862168 -
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective, Phase II Trial
|
Phase 2 | |
Recruiting |
NCT05451303 -
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
|
||
Recruiting |
NCT05902455 -
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
|
||
Not yet recruiting |
NCT05803915 -
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
|
Phase 2 |